# Lars Rydén

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lars-ryden-3/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,065 |
| Field | Diabetes Treatment and Management |
| h-index | 60 |
| i10-index | 163 |
| Last Known Institution | Karolinska Institutet |
| OpenAlex ID | https://openalex.org/A5082101100 |
| ORCID iD | https://orcid.org/0000-0003-3354-3063 |
| Works | 334 |

## Researcher papers

- [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)](https://scholariq.org/papers/european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice-5/)
- [2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD](https://scholariq.org/papers/2019-esc-guidelines-on-diabetes-pre-diabetes-and-cardiovascular-diseases/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure](https://scholariq.org/papers/comparative-effects-of-low-and-high-doses-of-the-angiotensin-converting-enzyme/)
- [Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry](https://scholariq.org/papers/lifestyle-and-impact-on-cardiovascular-risk-factor-control-in-coronary-patients/)
- [Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or/)
- [Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-analysis-of-the/)
- [Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin](https://scholariq.org/papers/safety-of-proton-pump-inhibitors-based-on-a-large-multi-year-randomized-trial-of/)
- [Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effects-of-acarbose-on-cardiovascular-and-diabetes-outcomes-in-patients-with/)
- [Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/effect-of-dulaglutide-on-cognitive-impairment-in-type-2-diabetes-an-exploratory/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac electrophysiology and arrhythmias](https://scholariq.org/topics/cardiac-electrophysiology-and-arrhythmias/)

## Researcher university

- [Karolinska Institutet](https://scholariq.org/institutions/karolinska-institutet/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.